Pharmac funds a new strength of thiamine hydrochloride injection

Pharmac will fund a new strength of thiamine hydrochloride injection, 50 mg per ml (2 ml ampoule), for use in Health New Zealand | Te Whatu Ora hospitals, from 1 April 2026.

Pharmac currently lists thiamine hydrochloride injection 100 mg per ml (1 ml vial and 2 ml vials) and injection 125 mg per ml (2 ml vial) in Part II of Section H of the Pharmaceutical Schedule. None of these line items have a contracted product and we understand most products meeting these descriptions are supplied under Section 29.

From April, the Thiamine Sterop brand of thiamine hydrochloride injection 50 mg per ml (2 ml ampoule) will be listed in Part II of Section H of the Pharmaceutical Schedule, reducing the administrative burden for health care professionals and providing certainty of ongoing supply for the people who need thiamine injections.

From 1 September 2026 until 30 June 2028, the Thiamine Sterop brand of thiamine hydrochloride injection will have Principal Supply Status with a 5% DV limit. This means that Thiamine Sterop will be the main funded brand of thiamine hydrochloride injection 50 mg per ml until 30 June 2028. The two current strengths of thiamine hydrochloride injections and the two strengths of thiamine hydrochloride tablets would remain listed in Part II of Section H of the Pharmaceutical Schedule for those who need it.

Find out more: Decision to fund a new strength of thiamine hydrochloride injection

Ngā mihi,

John Lowe | Therapeutic Group Manager

Te Pātaka Whaioranga | Pharmac | PO Box 10-254 | Level 9, 40 Mercer Street, Wellington www.pharmac.govt.nz